Skip to content

US · SNOA · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Sonoma Pharmaceuticals, Inc. (SNOA) intrinsic value and stock valuation

$0.72as of 2026-11-21 · Mkt cap 1.9M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Sonoma Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values SNOA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SNOA’s statements →

Sonoma Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Boulder, CO 80301 sonomapharma.com

How the business is doing

Fiscal 2012–2026, USD

Revenue
$19.5M+0.9% 5y CAGRd
20122026
Net income
-$-3.17M
20122026
Free cash flow
-$-4.12M
20122026
Total equity
$3.1M-10.4% 5y CAGRd
20122026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2026, USD
20262025202420232022
Revenue$19.5M$14.3M$12.7M$13.3M$12.6M
Operating income-$-2.46M-$-3.71M-$-4.7M-$-4.57M-$-5.89M
Net income-$-3.17M-$-3.46M-$-4.83M-$-5.15M-$-5.09M
EPSd-$-1.89M-$-2.79M-$-5.31M-$-15.15M-$-18.85M
Operating cash flow-$-3.93M-$-90K-$-2.4M-$-6.15M-$-4.25M
Capital expenditure-$-190K-$-80K-$-20K-$-270K-$-140K
Free cash flow-$-4.12M-$-170K-$-2.42M-$-6.42M-$-4.38M
Total assets$14M$13.7M$14.7M$16.2M$18.8M
Total debt$840K$300K$610K$850K$1.37M
Net debt-$-1.56M-$-5.07M-$-2.52M-$-2.97M-$-6.03M
Total equity$3.1M$4.41M$6.14M$7.98M$8.7M
Cash and short-term investments$2.4M$5.37M$3.13M$3.82M$7.4M
Income statement
20262025202420232022
Revenue$19.5M$14.3M$12.7M$13.3M$12.6M
Cost of revenue$12.1M$8.82M$7.99M$8.79M$8.63M
Gross profit$7.42M$5.46M$4.75M$4.48M$3.99M
Research and development expenses$2.27M$1.81M$1.87M$210K$120K
Selling, general and administrative expenses$7.61M$7.36M$7.58M$8.84M$9.76M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$9.88M$9.18M$9.45M$9.05M$9.88M
Cost and expenses$22M$18M$17.4M$17.8M$18.5M
Interest income$0.00$0.00$0.00$20K$0.00
Interest expense$0.00$0.00$0.00$0.00$10K
Depreciation and amortization$140K$140K$180K$120K$190K
Ebitda-$-2.32M-$-2.77M-$-4.86M-$-5.06M-$-5.22M
Operating income-$-2.46M-$-3.71M-$-4.7M-$-4.57M-$-5.89M
Total other income/expenses, net-$-960K$800K-$-330K-$-610K$470K
Income before tax-$-3.42M-$-2.91M-$-5.03M-$-5.18M-$-5.42M
Income tax expense-$-240K$550K-$-200K-$-30K-$-330K
Net income-$-3.17M-$-3.46M-$-4.83M-$-5.15M-$-5.09M
Weighted average shares outstanding$1.68M$1.24M$910K$340K$270K
Weighted average diluted shares outstanding$1.68M$1.24M$910K$340K$270K
Balance sheet
20262025202420232022
Cash and short-term investments$2.4M$5.37M$3.13M$3.82M$7.4M
Net receivables$5.43M$3.76M$5.99M$2.57M$2.41M
Inventory$3.65M$2.92M$2.72M$2.86M$2.66M
Total current assets$12.1M$12.7M$12.6M$13.8M$16.4M
Property, plant and equipment, net$910K$310K$650K$910K$880K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.86M$1.04M$2.19M$2.43M$2.42M
Total assets$14M$13.7M$14.7M$16.2M$18.8M
Accounts payable$1.92M$950K$610K$840K$1.64M
Short-term debt$370K$280K$520K$690K$1.06M
Deferred revenue$280K$640K$480K$160K$1.28M
Total current liabilities$4.83M$4.1M$3.72M$3.72M$5.82M
Long-term debt$470K$30K$90K$160K$310K
Deferred revenue, non-current$0.00$20K$90K$140K$180K
Total non-current liabilities$6.03M$5.19M$4.88M$4.54M$4.33M
Capital lease obligations$620K$90K$280K$420K$560K
Total liabilities$10.9M$9.28M$8.6M$8.25M$10.2M
Common stock$0.00$0.00$0.00$10K$0.00
Retained earnings-$-200.98M-$-197.81M-$-194.35M-$-189.51M-$-184.36M
Accumulated other comprehensive income (loss)-$-3.24M-$-4.38M-$-2.72M-$-3.42M-$-4.31M
Total equity$3.1M$4.41M$6.14M$7.98M$8.7M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$840K$300K$610K$850K$1.37M
Net debt-$-1.56M-$-5.07M-$-2.52M-$-2.97M-$-6.03M
Cash flow statement
20262025202420232022
Net income-$-3.17M-$-3.46M-$-4.83M-$-5.15M-$-5.09M
Depreciation and amortization$140K$140K$180K$120K$190K
Stock-based compensation$260K$220K$520K$670K$380K
Change in working capital-$-410K$2.48M$1.69M-$-1.86M$3.13M
Accounts receivable-$-120K$430K-$-230K$60K$1.97M
Inventory-$-470K-$-390K$180K$40K-$-100K
Accounts payable$870K$420K-$-280K-$-860K-$-160K
Net cash provided by operating activities-$-3.93M-$-90K-$-2.4M-$-6.15M-$-4.25M
Investments in property, plant and equipment-$-190K-$-80K-$-20K-$-270K-$-140K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-190K-$-80K-$0.00-$-260K-$-100K
Common stock issued$470K$3.08M$1.78M$2.87M$7.55M
Common stock repurchased$0.00-$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$480K$3.03M$1.68M$2.49M$7.4M
Net change in cash-$-2.98M$2.25M-$-690K-$-3.58M$3.18M
Cash at end of period$2.4M$5.37M$3.13M$3.82M$7.4M
Operating cash flow-$-3.93M-$-90K-$-2.4M-$-6.15M-$-4.25M
Capital expenditure-$-190K-$-80K-$-20K-$-270K-$-140K
Free cash flow-$-4.12M-$-170K-$-2.42M-$-6.42M-$-4.38M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Sonoma Pharmaceuticals, Inc.

        Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.

        CEO
        Amy Trombly
        Employees
        10
        Beta
        1.27

        Explore

        Frequently asked questions

        What is the intrinsic value of Sonoma Pharmaceuticals, Inc. (SNOA)?

        InvestorsCraft does not currently publish an intrinsic value for SNOA. How the IC value is calculated.

        Is SNOA undervalued?

        InvestorsCraft does not publish an undervaluation signal for SNOA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.